Med Plant Science (MPS) is a biotechnology company focused on developing advanced medications for the treatment of mental health conditions using active ingredients from psychedelic plants and fungi.
They’re focused on a patented nano-encapsulation technology that offers clinicians greater predictability in psychedelic dosing onset, potency, and duration of therapeutic experience.
In March of this year, the Calgary-based company was awarded a license for medicinal plants containing psychedelic compounds by the St. Vincent and the Grenadines (SVG) Bureau of Standards. The Scientific Research License allows for cultivation, processing, import/export of psychedelic compounds for medicinal purposes and scientific research. It applies to the following compounds: Psilocybin, Ketamine, Ibogaine, Ayahuasca, Dimethyltryptamine(DMT), Mescaline, 3-4 Methylenedioxy-Methamphetamine(MDMA), Lysergic Acid Diethylamide(LSD), 5-Methoxy-N,N-Dimethyltrypotomine(5-MeO-DMT), Turmeric, Aloe Vera, Papaya, Arrowroot, Soursop, Coconut, Ginger, Moringa, Iboga, Sassafras and Peyote.
The License is also expandable to allow Med Plant Science to offer access to clinical treatment facilities using psychedelics for mental health disorders.
CEO Angus Taylor and co-founder Craig Stenhouse joined Microdose at the recent Psychedelic Capital event to discuss their company and its focus on nano-encapsulation, a drug delivery system that combines with traditional therapy to optimize patient outcomes.
Angus Taylor, CEO:
Nano-encapsulation has got a number of advantages, principally it’s a method to reduce the size of active ingredient particles to the point where they’re more easily absorbed by the body. The technology itself is relatively simple, best described as kind of a bubble that forms around the active ingredient. The best analogy is to think of it as a sink of soapy or oily dishes, and when you add the detergent to the water, the oil seems to disappear. But what’s actually happening is that the oil particles are getting smaller and smaller as the surface area is increased, and eventually they become small enough that they become miscible which means that they’re not truly dissolved, but they’re small enough particles that you can’t actually see them.
And the technology partner that we’ve joined with (Nu Vessl) has enormous experience defending this IP. There’s 12 active patents on the technology currently, and what we’re licensed to do is use this technology for the full psychedelics spectrum. Any of the compounds that you saw previously listed are included in our agreements and we’re confident that we’ll have success with the defense of this technology in patent environments in the US and and the EU.
Using its license St. Vincent and the Grenadines, they’re working to supply active ingredients to the lucrative research market for clinical trials and are on-track to begin the first clinical trials in Canada using their rapid onset medication to treat alcoholism.
Med Plant Science is also the first company to be a part of Microdose’s Deal Board — a vehicle for all levels of investors to take part in early-stage investments. The company is looking to raise $1.8M CAD and everyday investors have a chance to be a part of it. See here for more information.
And click here for a look at Med Plant’s full presentation.
